Benefits and limitations of incretin-based therapies and sodium-glucose transporter 2 inhibitors on diabetic kidney disease

YI-CHIH LINSHAO-YU YANG2020-12-242020-12-2420161016-7390https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011911815&doi=10.6314%2fJIMT.2016.27%285%29.04&partnerID=40&md5=81344791fb34100c9815539211be2832https://scholars.lib.ntu.edu.tw/handle/123456789/531271[SDGs]SDG3Benefits and limitations of incretin-based therapies and sodium-glucose transporter 2 inhibitors on diabetic kidney diseasejournal article10.6314/JIMT.2016.27(5).042-s2.0-85011911815